Vitalgen's VGN-R09b Granted Orphan Drug Designation by U.S. FDA

Shanghai Vitalgen BioPharma Co., Ltd. recently announced that VGN-R09b, its independently developed gene therapy product for the treatment of Aromatic L-Amino Acid Decarboxylase Deficiency, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. This marks the second FDA designation received by VGN-R09b within a short period, following its previous Rare Pediatric Disease Designation. It represents another key regulatory endorsement in the global development process of VGN-R09b for the AADCD indication.

2026-01-28

Vitalgen's VGN-R08b Granted Orphan Drug Designation, Securing Three Key FDA Recognitions

Today, Shanghai Vitalgen BioPharma Co., Ltd. announced that VGN-R08b, its independently developed AAV gene therapy product for the treatment of Gaucher disease, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration.

2026-01-15

Vitalgen's VGR-R01 Granted PRIME Designation by the European Medicines Agency

Shanghai Vitalgen BioPharma Co., Ltd. recently announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has agreed to grant PRIME designation for VGR-R01 for the treatment of Bietti's crystalline dystrophy, supporting its development and accelerated assessment. The public information is as follows:

2025-12-19

Vitalgen's Independently Developed VGN-R09b Granted Rare Pediatric Disease Designation by U.S. FDA

Shanghai Vitalgen BioPharma Co., Ltd. recently announced that VGN-R09b, its independently developed gene therapy product for the treatment of Aromatic L-Amino Acid Decarboxylase Deficiency, has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. This designation represents another significant milestone for VGN-R09b following its official inclusion in the Breakthrough Therapy Designation list in China, highlighting the product's global development potential in the AADCD treatment landscape.

2025-12-01

Vitalgen's Second Gene Therapy Product VGN-R09b Proposed for Inclusion in the Breakthrough Therapy Designation List

Shanghai Vitalgen BioPharma Co., Ltd. recently announced that VGN-R09b, its independently developed gene therapy product for the treatment of Aromatic L-Amino Acid Decarboxylase Deficiency, has been proposed for inclusion in the Breakthrough Therapy Designation list by the Center for Drug Evaluation of the National Medical Products Administration. VGN-R09b is the company's second gene therapy product, following VGR-R01, to receive Breakthrough Therapy Designation and enter Phase III clinical trials, further demonstrating the company's sustained innovation capabilities and pipeline depth in the field of gene therapy.

2025-11-18

Vitalgen Achieves Dual Success: VGN-R08b Granted FDA Fast Track Designation, VGN-R09b Featured on Beijing Satellite TV

Shanghai Vitalgen BioPharma Co., Ltd. recently announced that VGN-R08b, its independently developed gene therapy product for GBA1 mutation-associated Parkinson's disease, has been granted Fast Track Designation by the U.S. Food and Drug Administration. The company's other gene therapy product for idiopathic Parkinson's disease, VGN-R09b, previously received this designation in June of this year. With these achievements, both core products in the company's Parkinson's disease portfolio have successfully completed regulatory filings in both China and the United States and have each been granted FTD, underscoring the high recognition of the company's innovative capabilities in neurological disorders by international regulatory authorities. VGN-R09b's clinical trial for idiopathic Parkinson's disease conducted at Beijing Aerospace Center Hospital has also been featured by Beijing Satellite TV due to its favorable therapeutic outcomes.

2025-10-23

China's First Investigational Gene Therapy for GBA1 Mutation-Associated Parkinson's Disease Receives Clinical Trial Approval: Vitalgen's Dual-Pipeline Strategy Strengthens Its Parkinson's Disease Therapeutic Portfolio

Shanghai Vitalgen BioPharma Co., Ltd. and its wholly-owned subsidiary Vitalgen (Shenzhen) BioPharma Co., Ltd. recently announced that the company's independently developed VGN-R08b has received Investigational New Drug clearance from both China's National Medical Products Administration and the U.S. Food and Drug Administration to conduct clinical studies for the treatment of GBA1 mutation-associated Parkinson's disease. This marks the company's second gene therapy product for Parkinson's disease to enter the clinical stage, following the 2024 IND clearances in both China and the U.S. for VGN-R09b, a gene therapy product for the treatment of idiopathic Parkinson's disease. With these approvals, Vitalgen has initially established a dual-track therapeutic strategy covering both idiopathic and genetic subtypes of Parkinson's disease.

2025-09-28

Vitalgen's LNP Technology Platform Empowers Multiple Partner Companies' R&D Pipelines, Achieving Positive Progress

Shanghai Vitalgen BioPharma Co., Ltd. recently announced that its proprietary lipid nanoparticle delivery technology platform has successfully entered into four technology out-licensing agreements. Partners' related R&D pipelines have subsequently received IND approvals or have advanced to the IIT stage.

2025-09-02

Vitalgen's ALS Gene Therapy VGN-R13 Yields Positive Clinical Results in Early Exploratory Clinical Study

On August 15, 2025, Shanghai Vitalgen BioPharma Co., Ltd. announced that its independently developed innovative gene therapy VGN-R13 for the treatment of amyotrophic lateral sclerosis has achieved significant progress in an early exploratory clinical study conducted at Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology. The study has completed enrollment of all subjects in the first dose cohort, demonstrating encouraging clinical results.

2025-08-15

Enrollment Completed for Phase I/III Clinical Trial of VGN-R09b in Patients with Severe Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency

Recently, Shanghai Vitalgen BioPharma Co., Ltd.has completed patient enrollment for its self-developed VGN-R09b in the Phase I/III registrational clinical trial of severe Aromatic L-Amino Acid Decarboxylase Deficiency .

2025-07-24